Loading…

Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats

This study investigated the effects of cilostazol on motor dysfunction, spinal motor neuron abnormalities, and schwannopathy in rats with diabetes. Diabetes mellitus (DM) was induced in rats via femoral intravenous streptozotocin (STZ) injection (60 mg/kg). After successful DM induction, cilostazol...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2024-07, Vol.25 (14), p.7847
Main Authors: Chang, Lin-Li, Wu, Yu-Ming, Wang, Hung-Chen, Tseng, Kuang-Yi, Wang, Yi-Hsuan, Lu, Yen-Mou, Cheng, Kuang-I
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c377t-2b15fbc55fb5e5ed210b784030589753b0c752957b1c92df5040c220160667633
container_end_page
container_issue 14
container_start_page 7847
container_title International journal of molecular sciences
container_volume 25
creator Chang, Lin-Li
Wu, Yu-Ming
Wang, Hung-Chen
Tseng, Kuang-Yi
Wang, Yi-Hsuan
Lu, Yen-Mou
Cheng, Kuang-I
description This study investigated the effects of cilostazol on motor dysfunction, spinal motor neuron abnormalities, and schwannopathy in rats with diabetes. Diabetes mellitus (DM) was induced in rats via femoral intravenous streptozotocin (STZ) injection (60 mg/kg). After successful DM induction, cilostazol was administered on day 15 via oral gavage (100 mg/kg/day) for 6 weeks until sacrifice. Behavioral assays, including motor function, were performed weekly. The sciatic nerve, L5 spinal cord, and spinal ventral root were collected to evaluate the expression of the glial fibrillary acidic protein (GFAP), myelin protein zero (P0), and choline acetyltransferase (ChAT) by immunofluorescence and Western blotting. DM rats displayed decreased running speeds, running distances, and toe spread but increased foot pressure. In addition, loss of non-myelinating Schwann cells and myelin sheaths was observed in the sciatic nerve and L5 spinal ventral root. Reduced numbers of motor neurons were also found in the L5 spinal ventral horn. Cilostazol administration significantly potentiated running speed and distance; increased hind paw toe spread; and decreased foot pressure. In the sciatic nerve and L5 spinal ventral root, cilostazol treatment significantly improved non-myelinated Schwann cells and increased myelin mass. ChAT expression in motor neurons in the spinal ventral horn was improved, but not significantly. Cilostazol administration may protect sensorimotor function in diabetic rats.
doi_str_mv 10.3390/ijms25147847
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_836b6553f60846c7baca5dca8f737839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A803762766</galeid><doaj_id>oai_doaj_org_article_836b6553f60846c7baca5dca8f737839</doaj_id><sourcerecordid>A803762766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-2b15fbc55fb5e5ed210b784030589753b0c752957b1c92df5040c220160667633</originalsourceid><addsrcrecordid>eNptkttrFDEUxgdRbK2--SwBX3zo1Fwml3lctlYXKoLV55BrzTKTrEkGaf96s26tVSSQhPD7vnO-cLruJYJnhIzwbdjOBVM0cDHwR90xGjDuIWT88YP7UfeslC2EmGA6Pu2Omo4RKMRxN63DlEpVt2kCq9lNIWVVXQEfU00ZnN8Uv0RTQ4pARQuuzLcfKkawdtMENvNOhTy7WEGI4Kpmt6vptulMiP0m2sU4C86D0q4GAz6rWp53T7yaintxd550Xy_efVl_6C8_vd-sV5e9IZzXHmtEvTa0bdRRZzGCuqWDBFIxcko0NJzikXKNzIitp3CABmOIGGSMM0JOus3B1ya1lbscZpVvZFJB_npI-Vqq3JqanBSEaUYp8QyKgRmulVHUGiU8J1yQsXm9OXjtcvq-uFLlHIpp-VV0aSmyfSNFSGC0L_v6H3Sblhxb0j01jAShQfyhrlWrH6JPNSuzN5UrAQlnmDPWqLP_UG1ZNweTovOhvf8lOD0ITE6lZOfvcyMo94MiHw5Kw1_d9bro2dl7-PdkkJ9LNbYS</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084931148</pqid></control><display><type>article</type><title>Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Chang, Lin-Li ; Wu, Yu-Ming ; Wang, Hung-Chen ; Tseng, Kuang-Yi ; Wang, Yi-Hsuan ; Lu, Yen-Mou ; Cheng, Kuang-I</creator><creatorcontrib>Chang, Lin-Li ; Wu, Yu-Ming ; Wang, Hung-Chen ; Tseng, Kuang-Yi ; Wang, Yi-Hsuan ; Lu, Yen-Mou ; Cheng, Kuang-I</creatorcontrib><description>This study investigated the effects of cilostazol on motor dysfunction, spinal motor neuron abnormalities, and schwannopathy in rats with diabetes. Diabetes mellitus (DM) was induced in rats via femoral intravenous streptozotocin (STZ) injection (60 mg/kg). After successful DM induction, cilostazol was administered on day 15 via oral gavage (100 mg/kg/day) for 6 weeks until sacrifice. Behavioral assays, including motor function, were performed weekly. The sciatic nerve, L5 spinal cord, and spinal ventral root were collected to evaluate the expression of the glial fibrillary acidic protein (GFAP), myelin protein zero (P0), and choline acetyltransferase (ChAT) by immunofluorescence and Western blotting. DM rats displayed decreased running speeds, running distances, and toe spread but increased foot pressure. In addition, loss of non-myelinating Schwann cells and myelin sheaths was observed in the sciatic nerve and L5 spinal ventral root. Reduced numbers of motor neurons were also found in the L5 spinal ventral horn. Cilostazol administration significantly potentiated running speed and distance; increased hind paw toe spread; and decreased foot pressure. In the sciatic nerve and L5 spinal ventral root, cilostazol treatment significantly improved non-myelinated Schwann cells and increased myelin mass. ChAT expression in motor neurons in the spinal ventral horn was improved, but not significantly. Cilostazol administration may protect sensorimotor function in diabetic rats.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms25147847</identifier><identifier>PMID: 39063088</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Amputation ; Cholesterol ; cholinergic neuron ; cilostazol ; Diabetes ; Diabetic neuropathy ; diabetic rat ; Hyperalgesia ; Hyperglycemia ; Ischemia ; motor neuron ; Nervous system ; neuropathy ; Pathogenesis ; Peripheral neuropathy ; Pharmaceutical industry ; Running ; schwannopathy ; Triglycerides</subject><ispartof>International journal of molecular sciences, 2024-07, Vol.25 (14), p.7847</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c377t-2b15fbc55fb5e5ed210b784030589753b0c752957b1c92df5040c220160667633</cites><orcidid>0000-0002-3766-6450 ; 0000-0003-1624-0562</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3084931148/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3084931148?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39063088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Lin-Li</creatorcontrib><creatorcontrib>Wu, Yu-Ming</creatorcontrib><creatorcontrib>Wang, Hung-Chen</creatorcontrib><creatorcontrib>Tseng, Kuang-Yi</creatorcontrib><creatorcontrib>Wang, Yi-Hsuan</creatorcontrib><creatorcontrib>Lu, Yen-Mou</creatorcontrib><creatorcontrib>Cheng, Kuang-I</creatorcontrib><title>Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>This study investigated the effects of cilostazol on motor dysfunction, spinal motor neuron abnormalities, and schwannopathy in rats with diabetes. Diabetes mellitus (DM) was induced in rats via femoral intravenous streptozotocin (STZ) injection (60 mg/kg). After successful DM induction, cilostazol was administered on day 15 via oral gavage (100 mg/kg/day) for 6 weeks until sacrifice. Behavioral assays, including motor function, were performed weekly. The sciatic nerve, L5 spinal cord, and spinal ventral root were collected to evaluate the expression of the glial fibrillary acidic protein (GFAP), myelin protein zero (P0), and choline acetyltransferase (ChAT) by immunofluorescence and Western blotting. DM rats displayed decreased running speeds, running distances, and toe spread but increased foot pressure. In addition, loss of non-myelinating Schwann cells and myelin sheaths was observed in the sciatic nerve and L5 spinal ventral root. Reduced numbers of motor neurons were also found in the L5 spinal ventral horn. Cilostazol administration significantly potentiated running speed and distance; increased hind paw toe spread; and decreased foot pressure. In the sciatic nerve and L5 spinal ventral root, cilostazol treatment significantly improved non-myelinated Schwann cells and increased myelin mass. ChAT expression in motor neurons in the spinal ventral horn was improved, but not significantly. Cilostazol administration may protect sensorimotor function in diabetic rats.</description><subject>Amputation</subject><subject>Cholesterol</subject><subject>cholinergic neuron</subject><subject>cilostazol</subject><subject>Diabetes</subject><subject>Diabetic neuropathy</subject><subject>diabetic rat</subject><subject>Hyperalgesia</subject><subject>Hyperglycemia</subject><subject>Ischemia</subject><subject>motor neuron</subject><subject>Nervous system</subject><subject>neuropathy</subject><subject>Pathogenesis</subject><subject>Peripheral neuropathy</subject><subject>Pharmaceutical industry</subject><subject>Running</subject><subject>schwannopathy</subject><subject>Triglycerides</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptkttrFDEUxgdRbK2--SwBX3zo1Fwml3lctlYXKoLV55BrzTKTrEkGaf96s26tVSSQhPD7vnO-cLruJYJnhIzwbdjOBVM0cDHwR90xGjDuIWT88YP7UfeslC2EmGA6Pu2Omo4RKMRxN63DlEpVt2kCq9lNIWVVXQEfU00ZnN8Uv0RTQ4pARQuuzLcfKkawdtMENvNOhTy7WEGI4Kpmt6vptulMiP0m2sU4C86D0q4GAz6rWp53T7yaintxd550Xy_efVl_6C8_vd-sV5e9IZzXHmtEvTa0bdRRZzGCuqWDBFIxcko0NJzikXKNzIitp3CABmOIGGSMM0JOus3B1ya1lbscZpVvZFJB_npI-Vqq3JqanBSEaUYp8QyKgRmulVHUGiU8J1yQsXm9OXjtcvq-uFLlHIpp-VV0aSmyfSNFSGC0L_v6H3Sblhxb0j01jAShQfyhrlWrH6JPNSuzN5UrAQlnmDPWqLP_UG1ZNweTovOhvf8lOD0ITE6lZOfvcyMo94MiHw5Kw1_d9bro2dl7-PdkkJ9LNbYS</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Chang, Lin-Li</creator><creator>Wu, Yu-Ming</creator><creator>Wang, Hung-Chen</creator><creator>Tseng, Kuang-Yi</creator><creator>Wang, Yi-Hsuan</creator><creator>Lu, Yen-Mou</creator><creator>Cheng, Kuang-I</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3766-6450</orcidid><orcidid>https://orcid.org/0000-0003-1624-0562</orcidid></search><sort><creationdate>20240701</creationdate><title>Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats</title><author>Chang, Lin-Li ; Wu, Yu-Ming ; Wang, Hung-Chen ; Tseng, Kuang-Yi ; Wang, Yi-Hsuan ; Lu, Yen-Mou ; Cheng, Kuang-I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-2b15fbc55fb5e5ed210b784030589753b0c752957b1c92df5040c220160667633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Amputation</topic><topic>Cholesterol</topic><topic>cholinergic neuron</topic><topic>cilostazol</topic><topic>Diabetes</topic><topic>Diabetic neuropathy</topic><topic>diabetic rat</topic><topic>Hyperalgesia</topic><topic>Hyperglycemia</topic><topic>Ischemia</topic><topic>motor neuron</topic><topic>Nervous system</topic><topic>neuropathy</topic><topic>Pathogenesis</topic><topic>Peripheral neuropathy</topic><topic>Pharmaceutical industry</topic><topic>Running</topic><topic>schwannopathy</topic><topic>Triglycerides</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Lin-Li</creatorcontrib><creatorcontrib>Wu, Yu-Ming</creatorcontrib><creatorcontrib>Wang, Hung-Chen</creatorcontrib><creatorcontrib>Tseng, Kuang-Yi</creatorcontrib><creatorcontrib>Wang, Yi-Hsuan</creatorcontrib><creatorcontrib>Lu, Yen-Mou</creatorcontrib><creatorcontrib>Cheng, Kuang-I</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Lin-Li</au><au>Wu, Yu-Ming</au><au>Wang, Hung-Chen</au><au>Tseng, Kuang-Yi</au><au>Wang, Yi-Hsuan</au><au>Lu, Yen-Mou</au><au>Cheng, Kuang-I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>25</volume><issue>14</issue><spage>7847</spage><pages>7847-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>This study investigated the effects of cilostazol on motor dysfunction, spinal motor neuron abnormalities, and schwannopathy in rats with diabetes. Diabetes mellitus (DM) was induced in rats via femoral intravenous streptozotocin (STZ) injection (60 mg/kg). After successful DM induction, cilostazol was administered on day 15 via oral gavage (100 mg/kg/day) for 6 weeks until sacrifice. Behavioral assays, including motor function, were performed weekly. The sciatic nerve, L5 spinal cord, and spinal ventral root were collected to evaluate the expression of the glial fibrillary acidic protein (GFAP), myelin protein zero (P0), and choline acetyltransferase (ChAT) by immunofluorescence and Western blotting. DM rats displayed decreased running speeds, running distances, and toe spread but increased foot pressure. In addition, loss of non-myelinating Schwann cells and myelin sheaths was observed in the sciatic nerve and L5 spinal ventral root. Reduced numbers of motor neurons were also found in the L5 spinal ventral horn. Cilostazol administration significantly potentiated running speed and distance; increased hind paw toe spread; and decreased foot pressure. In the sciatic nerve and L5 spinal ventral root, cilostazol treatment significantly improved non-myelinated Schwann cells and increased myelin mass. ChAT expression in motor neurons in the spinal ventral horn was improved, but not significantly. Cilostazol administration may protect sensorimotor function in diabetic rats.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39063088</pmid><doi>10.3390/ijms25147847</doi><orcidid>https://orcid.org/0000-0002-3766-6450</orcidid><orcidid>https://orcid.org/0000-0003-1624-0562</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1422-0067
ispartof International journal of molecular sciences, 2024-07, Vol.25 (14), p.7847
issn 1422-0067
1661-6596
1422-0067
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_836b6553f60846c7baca5dca8f737839
source Publicly Available Content Database; PubMed Central
subjects Amputation
Cholesterol
cholinergic neuron
cilostazol
Diabetes
Diabetic neuropathy
diabetic rat
Hyperalgesia
Hyperglycemia
Ischemia
motor neuron
Nervous system
neuropathy
Pathogenesis
Peripheral neuropathy
Pharmaceutical industry
Running
schwannopathy
Triglycerides
title Cilostazol Ameliorates Motor Dysfunction and Schwann Cell Impairment in Streptozotocin-Induced Diabetic Rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A57%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cilostazol%20Ameliorates%20Motor%20Dysfunction%20and%20Schwann%20Cell%20Impairment%20in%20Streptozotocin-Induced%20Diabetic%20Rats&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Chang,%20Lin-Li&rft.date=2024-07-01&rft.volume=25&rft.issue=14&rft.spage=7847&rft.pages=7847-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms25147847&rft_dat=%3Cgale_doaj_%3EA803762766%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c377t-2b15fbc55fb5e5ed210b784030589753b0c752957b1c92df5040c220160667633%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3084931148&rft_id=info:pmid/39063088&rft_galeid=A803762766&rfr_iscdi=true